184 results on '"Oosterveer, Maaike H."'
Search Results
2. Genetic deletion of hepatic NCOR1 protects from atherosclerosis by promoting alternative bile acid-metabolism and sterol excretion
3. Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia
4. Characterization of milk oligosaccharide and sialic acid content and their influence on brain sialic acid in a lean mouse model for gestational diabetes
5. High childhood serum triglyceride concentrations associate with hepatocellular adenoma development in patients with glycogen storage disease type Ia
6. Hepatocyte-specific glucose-6-phosphatase deficiency disturbs platelet aggregation and decreases blood monocytes upon fasting-induced hypoglycemia
7. Precision-cut liver slices as an ex vivo model to assess impaired hepatic glucose production
8. Endogenous Glucose Production in Patients With Glycogen Storage Disease Type Ia Estimated by Oral D-[6,6-2H2]-glucose.
9. Endogenous Glucose Production in Patients With Glycogen Storage Disease Type Ia Estimated by Oral D-[6,6-2H2]-glucose
10. Hyperglycemia, pregnancy outcomes and maternal metabolic disease risk during pregnancy and lactation in a lean gestational diabetes mouse model
11. Endogenous Glucose Production in Patients With Glycogen Storage Disease Type Ia Estimated by Oral D-[6,6-2H2]-glucose
12. Normalization of hepatic ChREBP activity does not protect against liver disease progression in a mouse model for Glycogen Storage Disease type Ia
13. Additional file 1 of Genetic deletion of hepatic NCOR1 protects from atherosclerosis by promoting alternative bile acid-metabolism and sterol excretion
14. Identification of the fructose transporter GLUT5 (SLC2A5) as a novel target of nuclear receptor LXR
15. Impaired SUMOylation of nuclear receptor LRH-1 promotes nonalcoholic fatty liver disease
16. Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic control
17. SUMOylation-Dependent LRH-1/PROX1 Interaction Promotes Atherosclerosis by Decreasing Hepatic Reverse Cholesterol Transport
18. A Prospective Study on Continuous Glucose Monitoring in Glycogen Storage Disease Type Ia: Toward Glycemic Targets
19. Hepatocytes contribute to residual glucose production in a mouse model for glycogen storage disease type Ia
20. Next-generation glycogen storage diseases
21. Dynamic Methods for Childhood Hypoglycemia Phenotyping: A Narrative Review
22. Increased atherosclerosis in a mouse model of glycogen storage disease type 1a
23. The NAD+ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced Obesity
24. Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR-associated protein 9–Mediated Gene Editing
25. TGR5 Activation Inhibits Atherosclerosis by Reducing Macrophage Inflammation and Lipid Loading
26. Hepatic glucose sensing and integrative pathways in the liver
27. Short-Chain Fatty Acids Protect Against High-Fat Diet–Induced Obesity via a PPARγ-Dependent Switch From Lipogenesis to Fat Oxidation
28. A retrospective in‐depth analysis of continuous glucose monitoring datasets for patients with hepatic glycogen storage disease: Recommended outcome parameters for glucose management
29. Impaired Very‐Low‐Density Lipoprotein catabolism links hypoglycemia to hypertriglyceridemia in Glycogen Storage Disease type Ia
30. LRH-1-dependent glucose sensing determines intermediary metabolism in liver
31. Enantiomer‐specific pharmacokinetics of D,L‐3‐hydroxybutyrate: Implications for the treatment of multiple acyl‐CoA dehydrogenase deficiency
32. Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a
33. Glycogen storage disease type 1a is associated with disturbed vitamin A metabolism and elevated serum retinol levels
34. Bile Salt Sequestration Induces Hepatic De Novo Lipogenesis Through Farnesoid X Receptor– and Liver X Receptorα–Controlled Metabolic Pathways in Mice
35. Fish Oil Does Not Prevent High Fat Diet-Induced Peripheral Insulin Resistance in Mice: 1258-P
36. Macrophage NCOR1 protects from atherosclerosis by repressing a pro-atherogenic PPARγ signature
37. Glucose‐6‐Phosphate Regulates Hepatic Bile Acid Synthesis in Mice
38. Exploiting epigenetics for the treatment of inborn errors of metabolism
39. Resistance to diet-induced adiposity in cannabinoid receptor-1 deficient mice is not due to impaired adipocyte function
40. Selective glucocorticoid receptor modulation prevents and reverses non-alcoholic fatty liver disease in male mice
41. Hepatic Carbohydrate Response Element Binding Protein Activation Limits Nonalcoholic Fatty Liver Disease Development in a Mouse Model for Glycogen Storage Disease Type 1a.
42. Macrophage NCOR1 protects from atherosclerosis by repressing a pro-atherogenic PPARγ signature.
43. Glycogen storage disease type 1a is associated with disturbed vitamin A metabolism and elevated serum retinol levels.
44. Exploiting epigenetics for the treatment of inborn errors of metabolism.
45. Mechanisms by Which Metabolic Reprogramming in GSD1 Liver Generates a Favorable Tumorigenic Environment
46. LRH-1-dependent programming of mitochondrial glutamine processing drives liver cancer
47. Selective Glucocorticoid Receptor Modulation Prevents and Reverses Nonalcoholic Fatty Liver Disease in Male Mice.
48. A systems biology approach reveals the physiological origin of hepatic steatosis induced by liver X receptor activation
49. A Computational Model for the Analysis of Lipoprotein Distributions in the Mouse: Translating FPLC Profiles to Lipoprotein Metabolism
50. Zonation of glucose and fatty acid metabolism in the liver: Mechanism and metabolic consequences
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.